The Patent Landscape of Generic Loratadine Phenylephrine Combinations
The over-the-counter (OTC) market for cold and allergy medications is a multibillion-dollar industry, with many consumers relying on products that combine antihistamines and decongestants to alleviate symptoms. One popular combination is loratadine and phenylephrine, which is used to treat runny nose, sneezing, and congestion. However, the patent landscape of generic versions of this combination is complex and has undergone significant changes in recent years.
What is Loratadine Phenylephrine?
Loratadine is an antihistamine that blocks the action of histamine, a chemical released by the body during an allergic reaction. Phenylephrine, on the other hand, is a decongestant that reduces nasal congestion by constricting blood vessels in the nose. When combined, loratadine and phenylephrine provide relief from multiple symptoms associated with colds and allergies.
Patent History of Loratadine Phenylephrine Combinations
The original patent for loratadine was granted to Schering-Plough Corporation in 1985 (US Patent 4,536,507). The patent covered the use of loratadine as an antihistamine for the treatment of allergic conditions. However, the patent did not cover the combination of loratadine and phenylephrine.
In 1996, Schering-Plough Corporation was granted a patent for a combination of loratadine and pseudoephedrine (US Patent 5,506,206). This patent covered the use of the combination for the treatment of cold and allergy symptoms. However, the patent did not cover the combination of loratadine and phenylephrine.
Generic Versions of Loratadine Phenylephrine Combinations
In 2002, the patent for the combination of loratadine and pseudoephedrine expired, allowing generic versions of the combination to enter the market. However, the patent for the combination of loratadine and phenylephrine was still in force.
According to DrugPatentWatch.com, a leading provider of patent information for the pharmaceutical industry, the patent for the combination of loratadine and phenylephrine was granted to Schering-Plough Corporation in 2003 (US Patent 6,514,473). The patent covered the use of the combination for the treatment of cold and allergy symptoms.
However, in 2010, the patent for the combination of loratadine and phenylephrine expired, allowing generic versions of the combination to enter the market.
Current Patent Landscape
Today, there are several generic versions of loratadine phenylephrine combinations available on the market. These generic versions are manufactured by various companies, including Teva Pharmaceuticals, Mylan Pharmaceuticals, and Sandoz.
According to DrugPatentWatch.com, there are currently no patents listed for the combination of loratadine and phenylephrine. This means that generic versions of the combination are no longer protected by patent law and can be manufactured and sold by any company.
Impact on the Market
The expiration of the patent for the combination of loratadine and phenylephrine has had a significant impact on the market. With the entry of generic versions of the combination, prices for OTC cold and allergy medications have decreased, making them more affordable for consumers.
Conclusion
In conclusion, the patent landscape of generic loratadine phenylephrine combinations is complex and has undergone significant changes in recent years. While the original patent for loratadine was granted in 1985, the patent for the combination of loratadine and phenylephrine expired in 2010, allowing generic versions of the combination to enter the market.
Key Takeaways
* The original patent for loratadine was granted in 1985.
* The patent for the combination of loratadine and pseudoephedrine expired in 2002.
* The patent for the combination of loratadine and phenylephrine expired in 2010.
* There are currently no patents listed for the combination of loratadine and phenylephrine.
* Generic versions of loratadine phenylephrine combinations are available on the market.
Frequently Asked Questions
1. Q: What is the difference between loratadine and phenylephrine?
A: Loratadine is an antihistamine that blocks the action of histamine, while phenylephrine is a decongestant that reduces nasal congestion.
2. Q: What is the patent landscape of generic loratadine phenylephrine combinations?
A: The patent for the combination of loratadine and phenylephrine expired in 2010, allowing generic versions of the combination to enter the market.
3. Q: What are the benefits of generic versions of loratadine phenylephrine combinations?
A: Generic versions of loratadine phenylephrine combinations are more affordable for consumers and provide the same relief from cold and allergy symptoms as branded versions.
4. Q: Who manufactures generic versions of loratadine phenylephrine combinations?
A: Various companies, including Teva Pharmaceuticals, Mylan Pharmaceuticals, and Sandoz, manufacture generic versions of loratadine phenylephrine combinations.
5. Q: Are generic versions of loratadine phenylephrine combinations safe?
A: Yes, generic versions of loratadine phenylephrine combinations are safe and effective, just like branded versions.
Sources
1. US Patent 4,536,507 (Schering-Plough Corporation, 1985)
2. US Patent 5,506,206 (Schering-Plough Corporation, 1996)
3. US Patent 6,514,473 (Schering-Plough Corporation, 2003)
4. DrugPatentWatch.com (accessed March 2023)
5. "Generic Drugs: A Review of the Literature" by the National Institutes of Health (2019)